Article

Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML

2024-10-15

Abstract excerpt

<title>Abstract</title> <p>BTX-A51, a first-in-class oral small molecule inhibitor of casein kinase 1α (CK1α) and cyclin dependent kinase (CDK) 7 and 9, induces apoptosis of leukemic cells by activating p53 and inhibiting expression of <italic>Mcl1.</italic> Here, we report on the results of the phase 1 clinical trial of BTX-A51 in patients with relapsed or refractory AML and MDS. Thirty-one patients were enrolle...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fea8d946-0109-5e69-9c01-e2ff06631a4a
DOI: 10.21203/rs.3.rs-4954060/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 9 closest

Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AMLDOI 10.21203/rs.3.rs-4954060/v1Read

CK2 inhibitor, CX-4945, enhances BH3 priming and promotes apoptosis of venetoclax-resistant AML by targeting antiapoptotic proteinsSemantic proximity Read

BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.Semantic proximity Read

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.Semantic proximity Read

RUNX1 Upregulation by Cytotoxic Drugs Promotes ApoptosisSemantic proximity Read

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastomaSemantic proximity Read

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.Semantic proximity Read

663P First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumorsSemantic proximity Read

A Phase I Trial of First-in-Human Alpha-Emitter Astatine-211-Labeled Anti-CD45 Antibody (211At-BC8-B10) in Combination with Fludarabine and TBI As Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS): Preliminary Results of Dose EscalationSemantic proximity Read

Targeted Alpha Therapy with [ <sup>225</sup> Ac]Ac-Macropa-Isatuximab for CD38-positive Hematological MalignanciesSemantic proximity Read